Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026
… company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully … filed against a key patent for its ADAR-mediated RNAediting platform Axiomer™. The opposition was filed in …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … 10 (LCA10). Presentation title : Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited …
… A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology Key Updates Dr. Peter A. Beal joins … of RNA-based therapeutics, particularly in the area of RNAediting. As an expert in the field of ADAR and A-to-I …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … November 20 at 1:20-2:00 p.m. GMT Presentation at the 1 st RNAEditing Summit During the 1 st RNAEditing Summit to be held …